Two new, simple, rapid and reproducible spectrophotometric methods have been developed for the determination of lamotrigine (LMT) both in pure form and in its tablets. The first method (method A) is based on the formation of a colored ion-pair complex (1:1 drug/dye) of LMT with bromocresol green (BCG) at pH 5.02±0.01 and extraction of the complex into dichloromethane followed by the measurement of the yellow ion-pair complex at 410 nm. In the second (method B), the drug-dye ion-pair complex was dissolved in ethanolic potassium hydroxide and the resulting base form of the dye was measured at 620 nm. Beer's law was obeyed in the concentration range of 1.5-15 µg mL-1 and 0.5-5.0 µg mL-1 for method A and method B, respectively, and the corresponding molar absorptivity values are 1.6932 x 10(4) and 3.748 x 10(4) L mol-1cm-1. The Sandell sensitivity values are 0.0151 and 0.0068 µg cm-2 for method A and method B, respectively. The stoichiometry of the ion-pair complex formed between the dug and dye (1:1) was determined by Job's continuous variations method and the stability constant of the complex was also calculated. The proposed methods were applied successfully for the determination of drug in commercial tablets.

Quetiapine (QTF) is a potent serotonin and dopamine receptor antagonist used to treat major depressive disorders and schizophrenia. A simple, precise, accurate and cost-effective titrimetric method for the determination of QTF in bulk drug and in its dosage forms has been developed and validated. The method is based on the potentiometric titration of QTF in glacial acetic acid with acetous perchloric acid using a modified glass-saturated calomel electrode system. The method is applicable over the range of 2.0 - 20.0 mg of QTF. The proposed method was successfully applied to the determination of QTF in its pharmaceutical dosage forms. The results obtained were favorably compared with those obtained using a reference method. The precision results, expressed by intra-day and inter-day relative standard deviation values, were satisfactory (RSD ≤ 1.2%). The accuracy was satisfactory as well (RE ≤ 1.33%). Excipients used as additives in pharmaceutical formulations did not interfere in the proposed procedures, as shown by the recovery study via standard addition technique with percentage recoveries in the range 98.25-101.0 %, with a standard deviation of ≤ 0.62-1.52%.

Three simple and sensitive spectrophotometric methods are described for the determination of ofloxacin (OFX) in pharmaceuticals and in spiked human urine. First and second methods are based on the measurement of absorbance of OFX in 0.1 M HCl at 293 nm (method A) and 0.1 M NaOH at 287 nm, respectively. The third method is based on the measurement of 2:1 complex formed between OFX and iron(III) in H2SO4 medium, the complex peaking at 420 nm (method C). The optimum conditions for all the three methods are optimized. Beer's law is obeyed over the ranges 0.63-12.5 using method A and method B, and 10-120 µg mL-1 using method C. The apparent molar absorptivity values are calculated to be 3.5 × 10(4), 2.76 × 10(4) and 2.51 × 10³ L mol-1cm-1 for method A, method B and method C, respectively. The Sandell sensitivity, limit of detection (LOD) and limit quantification (LOQ) values are also reported. All the methods were validated in accordance with current ICH guidelines. The developed methods were employed with high degree of precision and accuracy for the estimation of total drug content in commercial tablet formulations of DOX. The results obtained from human spiked urine are satisfactory and recovery values are in the range 95.5-106.6%.